Like Sipahi and colleagues1 reported an increased risk of cancer, particularly lung cancer, in patients treated with angiotensin-receptor blockers (ARBs) in a recent issue of The Lancet Oncology. This meta-analysis has undoubtedly received a lot of attention and prompted us to consider the class effect of drugs that block the renin-angiotensin system. The ONTARGET trial2 showed similar and nonsignificant effects of telmisartan (an ARB) and ramipril-an angiotensin-converting enzyme (ACE) inhibitor-on the incidence of cancer.
展开▼
